SCHEMBL3533800

SCHEMBL3533800

Cc1nc(-c2ccc(C(F)(F)F)nc2)sc1C(OCC(F)(F)F)c1ccc(C#N)c(F)c1

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
XDH P47989 2/20 0.34
ABCC4 O15439 1/20 0.34
ABCB11 O95342 1/20 0.34
PGR P06401 1/20 0.34
CHRM1 P11229 1/20 0.34
PDE4A P27815 1/20 0.34
BLVRB P30043 1/20 0.34
TARBP2 Q15633 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
ABCG2 Q9UNQ0 1/20 0.34
CYP11B1 P15538 9/20 0.33
CYP11B2 P19099 9/20 0.33
PPID Q08752 1/20 0.33
AAK1 Q2M2I8 1/20 0.33
FNTA P49354 1/20 0.33
FNTB P49356 1/20 0.33
TRPV4 Q9HBA0 1/20 0.33
TRPV3 Q8NET8 1/20 0.33
CACNA1H O95180 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3532538 0.91 FNTA (0.37) XDHABCC4ABCB11PGRCHRM1
SCHEMBL3530081 0.91 FNTA (0.37) XDHABCC4ABCB11PGRCHRM1
SCHEMBL3526029 0.88 XDH (0.33) XDHABCC4ABCB11PGRCHRM1
SCHEMBL3746758 0.88 NPC1 (0.39) CYP11B1CYP11B2
SCHEMBL3527873 0.87 PGGT1B (0.35) FNTAFNTB
SCHEMBL3530670 0.84 FNTA (0.35) XDHABCC4ABCB11PGRCHRM1
SCHEMBL3530910 0.83 AR (0.35) XDHABCC4ABCB11PGRCHRM1
SCHEMBL3530461 0.83 XDH (0.33) XDHABCC4ABCB11PGRCHRM1
SCHEMBL3533795 0.80 RET (0.35) XDHABCC4ABCB11PGRCHRM1
SCHEMBL3528585 0.80 PGGT1B (0.33) FNTAFNTB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1931337-B1 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2013-10-23 EP disclosed
US-7709481-B2 Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals SANOFI-AVENTIS (FR) 2010-05-04 US disclosed
US-20080261979-A1 Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals SANOFI-AVENTIS (FR) 2008-10-23 US disclosed
EP-1931337-A2 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2008-06-18 EP disclosed
WO-2007039177-A2 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (DE) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261979-A1 Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals PPARD, PPARA, PPARG XDH 1949/4885ABCC4 362/4885ABCB11 1378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.